It's hard enough to pick winners in biotech, but when companies try to
explain away bad trial data with "don't look at that, look at *this*"
post hoc analysis, all manner of alarms and sirens should go off in
investors' heads. And yet, for every rule there is an exception, and I
think Amicus Therapeutics (FOLD)
may just be that rare exception. While I realize that hope and belief
are more suited to theology than biotechnology, I do believe that
Amicus's lead drug is effective and safe, and I hope that a 12-month
follow-up of its pivotal study will be able to demonstrate that
sufficiently for the FDA to grant approval.
Read the full Seeking Alpha article here:
Don't Fold On Amicus Therapeutics Just Yet
No comments:
Post a Comment